In addition, borderline signals have been seen in clinical trials of semi-selected patients with NSCLC [4], and case reports describe exceptional responses to trastuzumab in other cancers with HER2 amplification, such as cholangiocarcinoma [12]. This evidence concerns the gene ERBB2 and cancer.